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Background/Aims: Patients with various chronic liver diseases frequently have increased body iron stores. Prohepcidin is an 
easily measurable precursor of hepcidin, which is a key regulator of iron homeostasis. This study investigated the serum 
prohepcidin levels in patients with various chronic liver diseases with various etiologies. Methods: Serum prohepcidin levels were 
measured in patients with chronic hepatitis C (CH-C) (n=28), nonalcoholic fatty liver disease (NAFLD) (n=24), and alcoholic liver 
disease (ALD) (n=22), and in healthy controls (n=25) using commercial ELISA. Serum interleukin 6 (IL-6) levels and blood iron 
indices were also measured. Results: The serum levels of both prohepcidin and IL-6 were significantly higher in CH-C patients 
than in healthy controls, and there was a positive correlation between the IL-6 and prohepcidin levels (r =0.505, p=0.020). The 
prohepcidin levels in ALD patients did not differ from those in controls, despite their significantly elevated IL-6 levels. There was 
a tendency for a negative correlation between serum prohepcidin levels and transferrin saturation in ALD patients (r =-0.420, 
p=0.051). Neither prohepcidin nor IL-6 was significantly elevated in the NAFLD group, despite the presence of elevated serum 
iron and ferritin levels. Conclusions: The role of prohepcidin may differ in different human liver diseases. In the setting of CH-C, 
both the serum prohepcidin and IL-6 levels were significantly elevated and were positively correlated with each other. (Korean J 
Hepatol 2010;16:288-294)
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INTRODUCTION
Iron is an essential element for all living organisms, and it is 
required in a wide range of metabolic processes, including DNA 
synthesis, oxygen transport, and energy production. However, 
excess body iron can be harmful, in part through the generation 
of oxygen radicals.
1 Body iron homeostasis is tightly controlled 
through iron absorption in the duodenum, utilization and storage 
according to bone marrow needs, and internal iron replenishment.
2
Various diseases arise from imbalances in iron homeostasis. 
Iron accumulation in the liver is common in patients with chronic 
liver diseases,
3 especially patients with chronic hepatitis C 
(CH-C),
4-7 alcoholic liver disease (ALD),
7-9 and nonalcoholic 
fatty liver disease (NAFLD).
7,10 Oxidative stress has been 
proposed as a mechanism of liver injury in these diseases.
The peptide hepcidin is proposed to be the key mediator of 
iron metabolism and systemic distribution. It is synthesized by 
hepatocytes in response to both iron overload and inflammatory 
stimuli.
11-13 Hepcidin acts by down-regulating both iron 
absorption and iron release of enterocytes and macrophages
14-17 
in response to high iron levels and inflammatory cytokines such 
as interleukin 6 (IL-6).
18
Despite enormous interest in the role of hepcidin, a lack of 
available methods for quantifying circulating hepcidin in clinical 
samples hampers investigation of the role of hepcidin in human 
disease. However, ELISA can easily be utilized to measure 
serum levels of prohepcidin, the precursor molecule.
19 Nevertheless, 
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reflects active hepcidin or just a non-functional precursor. 
Currently, the data concerning serum prohepcidin levels in 
patients with various chronic liver diseases and in healthy 
controls is very limited. 
The aims of the present study were to evaluate the serum 
prohepcidin levels in patients with CH-C, ALD, NAFLD, and 
healthy controls and to determine the clinical variables affecting 
serum prohepcidin levels, including blood iron, transferrin 
saturation (TS), ferritin, and IL-6.
MATERIALS AND METHODS
Subjects
Patients were enrolled at the Hepatology Department in Seoul 
National Bundang Hospital between December 2006 and 
December 2007.
The CH-C group included 28 patients with positive serum 
HCV RNA and anti-HCV for greater than 6 months. The ALD 
group included 22 patients who had consumed alcohol at least 
daily (80 g for men or 40 g for women) for more than 5 years, and 
in whom other liver diseases-viral hepatitis, drug-induced liver 
disease, and autoimmune and genetic liver diseases such as 
Wilson disease - had been excluded. The NAFLD group included 
24 patients who were diagnosed using NAFLD criteria: minimal 
alcohol use (<20 g/day in men or <10 g/day in women), elevated 
aminotransferase levels, compatible ultrasonographic findings, 
and appropriate exclusion of alcoholic liver disease and other 
etiologies as above. Patients with liver cirrhosis or hepatocellular 
carcinoma were excluded from the study. Subjects were 
consecutively enrolled among those patients amenable to 
participation in the study. The healthy control group included 25 
health-check examinees with no evidence of liver disease on 
laboratory or radiological examination. This study was performed 
with the approval of the Seoul National University Bundang 
Hospital Institutional Review Board (IRB). Informed consent 
was obtained from all subjects.
Measurement of serum iron indices
The serum iron concentration, unbound iron binding capacity, 
and serum ferritin concentration were measured simultaneously 
by spectrophotometry using the FerroZine method (TBA 200, 
Toshiba, Tokyo, Japan) and electrochemiluminescence 
immunoassay (E170, Roche, Basel, Switzerland), respectively, 
according to the manufacturer’s instructions. Transferrin saturation 
(TS, %) was calculated by dividing the serum iron level by the 
total iron binding capacity and multiplying the figure by 100. 
The cutoff levels for elevated TS and ferritin were 55% and 300 
μg/ml for men and 50% and 200 μg/ml for women, respectively, 
based on our previous study.
20
Measurement of serum prohepcidin and IL-6
Serum samples were stored at -80℃ and allowed to return to 
room temperature before analysis. Commercially available enzyme 
immunoassays were used to determine serum prohepcidin 
(Hepcidin Prohormone ELISA, DRG Instruments, Marburg, 
Germany) and IL-6 (Human IL-6 immunoassay, R&D Systems, 
Minneapolis, MN, USA) levels, according to the manufacturer’s 
instructions. We drew a standard curve for each measurement. 
All serum samples were measured in duplicate, and the average 
values were adopted.
Statistical analysis
Continuous variables are presented as means±standard 
deviations. Continuous variables were compared using the one 
way analysis of variance that was corrected by the DUNNETT’s 
method as multiple comparison test. Nominal data were 
compared using Fisher’s exact test or Pearson’s chi-square test, 
as appropriate. Simple linear regression was performed to 
determine the clinical correlates associated with iron overload. 
Statistical analyses were performed using SPSS software (SPSS 
12.0K for Windows; SPSS Korea, Seoul, Korea). P values <0.05 
were considered statistically significant.
RESULTS
Clinical features and serum iron indices of the
study subjects 
The clinical features and laboratory results, including serum 
iron indices in patients with CH-C, ALD, NAFLD, and healthy 
controls, are summarized in Table 1. Although the mean subject 
age was constant across all groups, the proportion of male 
patients was significantly higher in the ALD group. Serum 
aspartate aminotransferase level in patients with CH-C, ALD, 
alanine aminotransferase level in patients with CH-C, ALD, was 
higher aminotransferase and fasting glucose levels were higher 
in patients with CH-C, ALD, and NAFLD, compared to those 
seen in healthy controls. The serum total cholesterol level was 
significantly lower in the CH-C group compared to the healthy 290  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
Table 1. Comparative data for clinical features and serum iron indices in healthy controls and in patients with various liver diseases
H-C (n=25) CH-C (n=28) ALD (n=22) NAFLD (n=24)
Age (yr) 48.5±12.1 53.4±13.0 46.1±9.3 44.4±13.8
Sex (M:F) 11:14 14:14 21:1
† 16:8
BMI (kg/m
2) 22.34±2.67 24.19±2.74 24.38±3.07
† 26.63±3.21
‡
Diabetes mellitus, n (%) 0 1(3.6) 3(13.6) 3(12.5)
AST (IU/L) 23.0±6.1 42.0±26.5
* 68.8±109.8
† 50.4±35.6
ALT (IU/L) 19.6±8.4 54.4±41.8
* 42.5±31.1 95.3±78.6
‡
Fasting blood glucose (mg/dL) 83.9±8.2 93.6±9.6  106.3±45.9
† 99.4±26.9
Total cholesterol (mg/dl) 208.7±40.1 184.9±38.5
* 198.8±32.4 219.4±30.8
Hemoglobin (g/dL) 13.96±1.23 14.30±1.72 15.34±1.08
† 15.14±1.48
‡
Serum iron (μg/dL) 120.6±47.0 124.4±41.3 205.4±60.0
† 157.0±48.8
‡
TIBC (μg/dL) 334.2±37.8 348.2±54.3 367.8±38.0
† 361.3±51.1
TS (%) 37.0±15.9 36.8±13.8 56.6±18.0
† 44.4±16.3
TS >55% (men) or >50% (women), n (%) 5(20.0%) 3(10.7%) 12(54.5%)
† 6(25.0%)
Serum ferritin (μg/dL) 115.0±82.7 157.4±168.0 322.3±402.7
† 283.9±309.1
Serum ferritin >300 μg/L (men) or >200 μg/L (women), n (%) 1(4.0%) 4(14.3%) 5(22.7%) 8(33.3%)
‡
H-C, healthy controls; CH-C, chronic hepatitis C; ALD, alcoholic liver disease; NAFLD, nonalcoholic fatty liver disease; BMI, body mass
index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TIBC, total iron binding capacity; TS, transferrin saturation.
* P<0.05 between CH-C patients and H-C.
† P<0.05 between ALD patients and H-C.
‡ P<0.05 between NAFLD patients and H-C.
Figure 1. Positive correlation between serum prohepcidin and 
interleukin-6 (IL-6) levels in patients with chronic hepatitis C 
(CH-C).
Figure 2. Negative correlation between the serum prohepcidin 
level and transferrin saturation (TS) in patients with alcoholic 
liver disease (ALD).
control group. 
The mean serum TS was significantly higher in the ALD 
group (p<0.001), and the mean serum ferritin levels were 
significantly higher in the ALD group (p=0.023) compared to 
those seen in the healthy control group. Neither TS nor ferritin 
was significantly elevated in the CH-C group, although the 
serum ferritin levels of CH-C patients showed an increasing 
tendency compared to those of the healthy control group.
Serum prohepcidin and IL-6 levels in CH-C,
ALD, NAFLD, and healthy controls 
The serum levels of prohepcidin and IL-6 in the patients with 
CH-C, ALD, NAFLD, and healthy control patients are 
summarized in Table 2. Both the serum prohepcidin and IL-6 
levels were significantly higher in the CH-C group than in the 
healthy control group (p<0.001 and p<0.001, respectively). The 
serum prohepcidin level in the ALD group was no different from Sang Hyub Lee, et al. Prohepcidin in liver diseases  291
Table 2. Comparative data for prohepcidin and interleukin-6 (IL-6) levels in healthy controls and in patients with various liver diseases
H-C (n=25) CH-C (n=28) ALD (n=22) NAFLD (n=24)
Serum Pro-hepcidin (ng/mL) 184.70±60.49 308.45±116.43
* 200.42±63.55 178.69±38.86
Serum IL-6 (pg/mL) 1.25±0.68 (N=15)
† 358.60±242.11
*  (N=21)
† 438.29±336.86
‡  (N=7)
† 0.95±0.75 (N=11)
†
Serum Pro-hepcidin/Serum ferritin ratio 2.62±2.38    4.70±5.65    1.17±0.85 1.37±1.49
IL-6, Interleukin-6; H-C, healthy controls; CH-C, chronic hepatitis C; ALD, alcoholic liver disease; NAFLD, nonalcoholic fatty liver 
disease. BMI, Body mass index; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; TIBC, Total iron binding capacity; 
TS, Transferrin saturation.
* P<0.05 between CH-C patients and H-C.
† IL-6 level was measured only in 15 healthy controls, 21 patients with chronic hepatitis C, 7 patients with alcoholic liver disease 
and 11 patients with nonalcoholic fatty liver disease.
‡ P<0.05 between ALD patients and H-C.
that seen in the healthy control group, despite significantly 
elevated IL-6 levels (438.29±336.86 pg/ml in ALD vs. 1.25±0.68 
pg/ml in healthy controls, p<0.001). In the NAFLD group, 
neither the serum prohepcidin level nor the IL-6 level was 
different compared to that seen in healthy controls.
Correlation between serum prohepcidin level 
and other variables
A positive correlation was found between serum prohepcidin 
levels and serum IL-6 levels in patients with CH-C (r=0.505, 
p=0.020, Fig. 1). However, the correlation was not significant in 
healthy controls, ALD, or NAFLD patients.
A negative correlation tendency was found between serum 
prohepcidin levels and TS in patients with ALD (r=-0.420, 
p=0.051, Fig. 2). However, the correlation was not statistically 
significant in the healthy, CH-C, or NAFLD groups. There was 
no significant correlation between serum prohepcidin and ferritin 
levels among the four groups of subjects.
Prohepcidin/ferritin ratios in CH-C, ALD,
NAFLD, and healthy controls
When we compared the prohepcidin/ferritin ratios among the 
four subject groups, there was no significant difference in the 
CH-C group (4.70±5.65, p=0.067), the ALD group (1.17±0.85, 
p=0.830) and the NAFLD group (1.37±1.49, p=0.422) compared 
to the healthy control group (2.62±2.38), although the ratio in the 
CH-C group and the healthy control group showed relatively 
higher level than others. 
There was a negative correlation between the prohepcidin/ 
ferritin ratio and TS in healthy controls (r=-0.448, p=0.025) and 
in patients with CH-C (r=0.-417,  p=0.030). However, this 
correlation was not significant in patients with ALD or NAFLD.
DISCUSSION
In this study, we observed that both the serum prohepcidin and 
IL-6 levels were significantly elevated in CH-C patients 
compared to those in healthy controls, and both prohepcidin and 
IL-6 were positively correlated with each other in CH-C. ALD 
patients showed significantly higher serum iron and ferritin 
levels compared to healthy controls, but their serum prohepcidin 
levels were not different from those seen in healthy controls, 
despite the significantly elevated IL-6 levels. Although the 
NAFLD group showed elevated serum iron and ferritin levels, 
neither the prohepcidin nor the IL-6 levels were elevated. 
Therefore, in CH-C, prohepcidin seems to be induced by IL-6. 
However, in ALD, prohepcidin is not induced by IL-6, probably 
due to the inhibitory effect of alcohol on hepcidin. Moreover, 
there was a negative correlation between the prohepcidin/ferritin 
ratio and TS in healthy and CH-C patients, while no such 
significant correlation was noted in ALD and NAFLD patients. 
This suggests that the prohepcidin response to body iron stores is 
functional in normal and CH-C patients, while it might be 
dysfunctional in ALD and NAFLD patients. Therefore, different 
regulatory mechanisms of iron metabolism and different roles of 
prohepcidin exist in different human liver diseases.
Hepcidin is the product of the hepcidin antimicrobial peptide 
(HAMP) gene on human chromosome 19, and expression of 
hepcidin mRNA is mostly confined to the liver. The transcript 
encodes a precursor protein of 84 amino acids, whereas the 
mature circulating bioactive forms of hepcidin consist of only the 
carboxy-terminal portion of 20-25 amino acids, which is 
cysteine-rich.
12 Serum hepcidin is not easily measured due to 
structural containment. Conversely, serum prohepcidin can be 
measured using a commercialized ELISA kit. Kulaksiz et al.
19 
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German volunteers (n=26) was 106.2 ng/ml. Thereafter, the 
serum prohepcidin levels measured by the same method were 
reported to be 85.1±6.1 ng/ml in female Korean college students 
(n=82),
21 and to be 227±207 ng/ml in Finnish women (n=37) and 
254±201 ng/ml in Finnish men (n=16),
22 findings quite similar to 
our own findings for healthy control subjects (184.7±60.5 ng/ml).
HCV infection is associated with alterations in body iron 
homeostasis through a poorly understood mechanism. Nagashima 
et al.
23 reported that prohepcidin levels in CH-C (n=137) and 
HCV-related liver cirrhosis (n=37) patients were 137.3±140.2 
ng/ml and 53.2±116.7 ng/ml, respectively, significantly lower 
than those seen in healthy controls (n=103), 448.5±200.7 ng/ml. 
Furthermore, hepcidin expression in the liver was negatively 
correlated with the total iron score in 49 patients. In their study, 
serum prohepcidin levels were quite high in healthy controls 
compared to other studies, including our results. Their findings 
with regard to the relationship between intrahepatic hepcidin 
expression and hepatic iron deposition contradicted the results of 
Aoki et al.,
24 which showed that hepcidin mRNA expression 
correlated with hepatic iron concentration and serum ferritin 
levels in liver biopsy samples obtained from chronic hepatitis C 
patients. Our findings contrast with those of Nagashima et al, but 
are compatible with the last study. Moreover, we found that the 
ratios of prohepcidin/ferritin in the healthy control group and in 
the CH-C groups were no different, and there was a negative 
correlation between the prohepcidin/ferritin ratio and TS in 
healthy controls (r=-0.448, p=0.025) and patients with CH-C 
(r=0.-417, p=0.030); this correlation did not exist in ALD and 
NAFLD patients. These findings may indicate that the 
prohepcidin response to body iron stores is functional in healthy 
controls and CH-C patients, while it is dysfunctional in ALD and 
NAFLD patients.
Our findings related to serum IL-6 levels in CH-C patients 
were compatible with several previous studies. Serum IL-6 
levels are significantly elevated in chronic hepatitis C patients 
compared to healthy controls,
25 and HCV induces IL-6 production 
by inducing Toll-like receptor 4 expression in vitro
26 or Toll-like 
receptor 2 expression in vivo.
27 In human liver cell cultures, as 
well as in mouse and human volunteer studies, IL-6 is the 
necessary and sufficient cytokine for the induction of hepcidin 
during inflammation.
28 Therefore, the significantly increased 
serum IL-6 and prohepcidin levels seen in CH-C patients in this 
study support the idea that HCV infection induces IL-6 
expression, which in turn induces hepcidin and serum prohepcidin 
expression. However, a recent study in a transgenic mouse model 
expressing HCV polyprotein showed a mild elevation of hepatic 
iron compared with nontransgenic mice, and this elevation was 
associated with a reduction in hepatic hepcidin mRNA expression 
and a reduction in serum prohepcidin protein levels.
29 However, 
this mouse model did not exhibit inflammation via the 
IL-6-mediated STAT2 signaling pathway, nor were cytokine 
changes noted in the human. Our clinical observations were in 
contrast to the mouse model, therefore, this model may not apply 
to human patients with chronic hepatitis C.
Hepcidin expression is reported to be consistently downregulated 
by alcohol in rat models with alcoholic liver disease and in vitro 
cell culture models.
30 Alcohol metabolism-mediated oxidative 
stress down-regulates hepcidin transcription via reduced CCAAT 
enhancer binding protein alpha activity and leads to increased 
duodenal iron transporter expression.
31 Ohtake et al. showed that 
serum prohepcidin levels in ALD patients (n=47), including 8 
cirrhosis patients, were significantly lower than those in 9 
healthy subjects (710±540 ng/ml vs. 1,570±260 ng/ml), and the 
serum prohepcidin/ferritin ratios in ALD and healthy subjects 
were 4.8±5.8 and 13.4±7.5, respectively (p<0.05).
32 Although 
the prohepcidin levels in healthy control subjects were unusually 
high compared to other studies, the ratio of prohepcidin/ferritin 
in ALD patients was significantly lower than that seen in healthy 
controls, which was consistent with our findings. We noted no 
significant difference in the serum prohepcidin levels between 
ALD and healthy control patients. However, serum IL-6 levels 
were significantly elevated in ALD patients, which was compatible 
with previous reports.
33 This suggests that prohepcidin was not 
induced in ALD, despite the elevation of IL-6.
Insulin resistance, the initial triggering factor of NAFLD, is 
closely related to hyperferritinemia, and hepatic iron could 
promote oxidative stress, the second factor in NAFLD pathogenesis 
and a probable downregulator of hepcidin. A recent study 
reported hepcidin expression in adipose tissue of severely obese 
patients, suggesting that severe obesity itself causes hypoferremia 
through overproduction of hepcidin in adipocytes and liver 
tissue, which may negate the effect of oxidative stress on 
hepcidin expression.
34 In our study, the serum prohepcidin levels 
in NAFLD patients were not different from those seen in healthy 
controls. However, the prohepcidin/ferritin ratio in NAFLD 
patients was significantly lower than that seen in healthy 
controls. This finding was similar to that in a recently reported 
study,
35 and could be explained by hyperferritinemia in NAFLD.
The basic limitation of this study was the measurement of 
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of the unavailability of such a measuring method. Serum 
prohepcidin levels have considerable interindividual variations, 
and commercially available ELISA kits suffer from low sensitivity, 
despite their high cost. Our study was also limited in that the 
sample sizes were small for each liver disease group, and hepatic 
hepcidin expression was not measured. However, the diagnostic 
classification of our subjects was strict, and the clinical data 
showed typical patterns with regard to disease. In addition, we 
obtained complete data for serum iron indices and other blood 
chemistry and clinical variables, which made it possible to 
analyze the prohepcidin/ferritin ratio and to determine its 
correlation with TS. To our knowledge, comparative studies on 
the serum prohepcidin levels in healthy subjects and in those 
with various liver diseases were limited.
In conclusion, the regulation of prohepcidin and probably 
hepcidin is complex and variable in the different liver diseases. 
In the setting of CH-C, both the serum prohepcidin and IL-6 
levels were significantly elevated and had positive correlation.
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